Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing

T C Felizardo1, J C M Wang, R A J McGray

  • 1Campbell Family Cancer Research Institute and Ontario Cancer Institute, University Health Network, Toronto, Ontario, Canada.

Gene Therapy
|April 15, 2011
PubMed

Insights

This study compared adenoviral and lentiviral HER-2 cancer vaccines in mice. Both controlled tumor growth, but viral vectors induced distinct immune responses, influencing T-cell types and cytokine production for antitumor immunity.

Area of Science:

  • Immunology
  • Oncology
  • Virology

Background:

  • Adenoviral and lentiviral vectors encoding HER-2 are used in cancer immunotherapy.
  • The comparative immune response of these viral systems is not well understood.

Purpose of the Study:

  • To compare the immune responses induced by dendritic cells (DCs) infected with either recombinant adenovirus or lentivirus encoding rat HER-2 (rHER-2).
  • To evaluate the impact of viral vector systems on antitumor immunity.

Main Methods:

  • Mice were immunized with dendritic cells (DCs) infected with adenovirus or lentivirus encoding rat HER-2 (rHER-2).
  • Immune responses, including T-cell infiltration, cytokine production (IFN-γ), and humoral response, were analyzed.
  • Tumor growth inhibition was assessed via adoptive transfer of splenocytes.

Main Results:

  • Both vaccine types controlled tumor growth similarly.
  • Adenovirus-transduced DCs induced higher frequencies of CD4+ and CD8+ T cells, while lentivirus-transduced DCs primarily led to CD4+ T-cell infiltration.
  • Lentivirus vaccination resulted in higher IFN-γ secretion mainly by CD4+ T cells, whereas adenovirus vaccination showed IFN-γ production from both CD4+ and CD8+ T cells.
  • Adenovirus vaccination elicited a stronger humoral response.

Conclusions:

  • The viral vector system, in addition to the target antigen, influences the nature and magnitude of antitumor immunity generated by DC vaccination.
  • Both adenoviral and lentiviral HER-2/DC vaccines promote significant antitumor immunity, but through distinct immune response profiles.

Related Concept Videos